Education
About Us
Working with TipRanks
Follow Us
OS Therapies Incorporated (OSTX)
:OSTX
OSTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $7.00
Previous CloseN/A
Volume28.07K
Average Volume (3M)628.90K
Market Cap
$70.16M
Enterprise Value$46.22M
Total Cash (Recent Filing)$2.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Nov 14, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding31,891,933
10 Day Avg. Volume728,488
30 Day Avg. Volume628,904
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-403.34
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside468.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesPositive updated interim 2-year overall survival data shows 66.6% of OST-HER2 treated patients achieved 2-year overall survival compared to 40% for historical control.
Regulatory DesignationsOST-HER2 holds FDA Orphan, Fast Track, and Rare Pediatric Disease designations, making it eligible for a priority review voucher, representing a significant opportunity for non-dilutive capital.
Regulatory ProgressThe company continues to make progress toward a potential rolling BLA filing, including an End-of-Phase 2 meeting with FDA scheduled, which suggests a favorable outlook for accelerated approval.
Bears Say
Adverse Events13 out of 40 patients experienced severe adverse events, with 7 cases being treatment-associated.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.12 and its highest was $7.00 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $70.16M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Nov 14, 2025 which is in 67 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on Aug 19, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.075.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.1.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 31,891,933 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went down -1.376%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
OS Therapies Incorporated Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (468.18% Upside)
$12.50 (468.18% Upside)
Blogger Sentiment
Bullish
OSTX Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
668.17%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$12.50
▲(468.18% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Adverum Biotechnologies
―
Annovis Bio
―
Gain Therapeutics
―
Klotho Neurosciences
―
Ownership Overview
16.58% Insiders
1.48% Other Institutional Investors
81.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---